biostudies-literatureUnknown78Yu Z<h4>Background</h4>Multiple myeloma (MM) is still an incurable malignancy of plasma cells. Proteasome inhibitors (PIs) work as the backbone agent and have greatly improved the outcome in majority of newly diagnosed patients with myeloma. However, drug resistance remains the major obstacle causing treatment failure in clinical practice. Here, we investigated the effects of Indirubin-3'-monoxime (I3MO), one of the derivatives of Indirubin, in the treatment of MM.<h4>Methods</h4>MM patient primary samples and human cell lines were examined. I3MO effects on myeloma treatment and the underling molecular mechanisms were investigated via in vivo and in vitro study.<h4>Findings</h4>Our results demonstrated the anti-MM activity of I3MO in both drug- sensitive and -resistance MM cells. I3MO sensitizEBioMedicine103950https://www.ebi.ac.uk/biostudies/studies/S-EPMC8958548biostudies-literatureIndirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.PMC8958548Huang CLiu LHao MWei XAn GWang KZhao YAnderson KCWang LQiu LMeng FCheng TLi YHe YFang TSui WHuang WYu TYu ZSun HfalseIndirubin-3'-monoxime acts as proteasome inhibitor: Therapeutic application in multiple myeloma.<h4>Background</h4>Multiple myeloma (MM) is still an incurable malignancy of plasma cells. Proteasome inhibitors (PIs) work as the backbone agent and have greatly improved the outcome in majority of newly diagnosed patients with myeloma. However, drug resistance remains the major obstacle causing treatment failure in clinical practice. Here, we investigated the effects of Indirubin-3'-monoxime (I3MO), one of the derivatives of Indirubin, in the treatment of MM.<h4>Methods</h4>MM patient primary samples and human cell lines were examined. I3MO effects on myeloma treatment and the underling molecular mechanisms were investigated via in vivo and in vitro study.<h4>Findings</h4>Our results demonstrated the anti-MM activity of I3MO in both drug- sensitive and -resistance MM cells. I3MO sensitiz2022-01-01T00:00:00Z2022 Apr2026-05-31T06:03:30.44Z2025-04-20T00:20:02.408ZS-EPMC89585483534476410.1016/j.ebiom.2022.103950